[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP4087558A1 - Formulations de paclitaxel comprenant des polymères séquencés poly(acide aminé) - Google Patents

Formulations de paclitaxel comprenant des polymères séquencés poly(acide aminé)

Info

Publication number
EP4087558A1
EP4087558A1 EP20704965.1A EP20704965A EP4087558A1 EP 4087558 A1 EP4087558 A1 EP 4087558A1 EP 20704965 A EP20704965 A EP 20704965A EP 4087558 A1 EP4087558 A1 EP 4087558A1
Authority
EP
European Patent Office
Prior art keywords
paclitaxel
weight
composition
copolymer
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20704965.1A
Other languages
German (de)
English (en)
Inventor
Kevin N. Sill
Bradford T. Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tyndall Formulation Services LLC
Original Assignee
Tyndall Formulation Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyndall Formulation Services LLC filed Critical Tyndall Formulation Services LLC
Publication of EP4087558A1 publication Critical patent/EP4087558A1/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Definitions

  • This invention relates to the field of formulations of paclitaxel and a poly(amino acid) copolymer and methods of making and using thereof.
  • Paclitaxel is a natural product isolated from the bark of the Pacific yew tree
  • Paclitaxel promotes the assembly of microtubules and inhibits depolymerization simultaneously which disrupts mitosis and ultimately triggers apoptosis.
  • the structure of paclitaxel is:
  • Taxol ® was the first paclitaxel formulation to be approved by the U.S. Food and Drug Administration (FDA) and is indicated for the treatment of ovarian, breast, non-small cell lung cancer, and Kaposi’s sarcoma.
  • FDA U.S. Food and Drug Administration
  • This original formulation is now generic and is one of the most commonly prescribed anti-cancer therapies. Varying vial amounts of paclitaxel are available, but each mL of these formulations contains 6 mg paclitaxel, 527 mg of purified Cremophor ® EL (polyoxyethylated castor oil) and 49.7% (v/v) dehydrated ethanol.
  • Cremophor EL is known to cause several infusion related side effects, including bronchospasm, hypotension, peripheral neuropathy, and anaphylactic reactions. These side effects necessitate pre-medication with H 1 and H 2 antagonists and prolonged infusion times to reduce the hypersensitivity reactions for Cremophor EL based paclitaxel formulations (see: Authier, N. et al, Neurotox. Res. 2001, 3, 301-306; Gelderblom, H. et al, Eur. J. Cancer 2001, 37, 1590-1598; Brat, D. et al, Pharmacology Exp. Ther.1992, 261, 803- 810; Windebank, A.J. et al., J. Pharmacology Exp. Ther.1994, 268, 1051-1056; Van Zuylen, L. et al., Investigational New Drugs, 2001, 19, 125-141.
  • Taxol and its generic equivalents because Cremophor EL extracts the plasticizer DEHP (di(2- ethylhexyl)phthalate) from polyvinyl chloride (PVC) materials. Furthermore, paclitaxel can become entrapped in Cremophor micelles which results in non-linear pharmacokinetics (see: Sparreboom, A. et al., Cancer Res, 1999, 59, 1454-1457.
  • the second approved formulation of paclitaxel was Abraxane ® (nab-paclitaxel), which was developed by Abraxis BioSciences, and is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and adenocarcinoma of the pancreas.
  • Abraxane is an albumin-bound formulation of paclitaxel. Although this formulation eliminates the need for Cremophor EL, the inclusion of human derived albumin theoretically poses a risk for transmission of viral diseases or Creutzfeldt-Jakob disease. Additionally, preparation of Abraxane for administration can be problematic and care must be taken to add the reconstitution media in a manner to avoid foaming and clumping.
  • Synthetic polymers excipients are an attractive option to formulate such greasy active pharmaceutical ingredients (APIs).
  • APIs greasy active pharmaceutical ingredients
  • PEG poly( ethylene glycol)
  • PLA poly(lactic acid)
  • PGLA poly (lactic acid-co-glycolic acid)
  • CD cyclodextrins
  • Many such polymers used for the parenteral delivery of drugs are non-degradable and can accumulate in tissue or the blood stream for prolonged periods of time.
  • paclitaxel formulation that does not require reconstitution in Cremophor EL for administration to a patient. It will also be recognized that there is a need for a paclitaxel drug product kit that contains a single vial, that maintains stability and potency, that can be reconstituted in a common parenteral diluent for administration to a patient.
  • the present disclosure provides a composition comprising paclitaxel and a poly(amino acid) block copolymer excipient. Also provided is a composition described herein for use in treating cancer. Also provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition or a unit dose form described herein. Also provided herein are methods of preparing a composition or a unit dose form described herein.
  • Figure 1 Rat Pharmacokinetic profile of TYN-21 versus Abraxane at equivalent paclitaxel dose of 5.0 mg/kg
  • the present disclosure is directed to a composition which comprises paclitaxel and a poly(amino acid) block copolymer as depicted in Formula I: wherein: x is 175 y is 30-35 x is 20-25
  • compositions comprising paclitaxel and a compound represented by Formula I.
  • Such compositions are pharmaceutically acceptable drug products suitable for administration to human patients.
  • the present disclosure is directed to methods for the treatment of cancers comprising administration of a composition comprising paclitaxel and a compound represented by Formula I.
  • paclitaxel refers to 5 ⁇ ,20-epoxy-
  • TFS-2 refers to a formulation comprising paclitaxel, TFS-2, and trehalose wherein the paclitaxel is about 13% weight loading of the formulation.
  • block copolymer refers to a polymer comprising two or more poly(amino acid) portions.
  • one or more of the amino acid blocks may be “mixed blocks”, meaning that these blocks can contain a mixture of amino acid monomers thereby creating block copolymers of the present disclosure.
  • a monomer repeat unit is defined by parentheses depicted around the repeating monomer unit. The number (or letter representing a numerical range) on the lower right of the parentheses represents the number of monomer units that are present in the polymer chain. In the case where only one monomer represents the block (e.g. a homopolymer), the block will be denoted solely by the parentheses.
  • brackets will define a portion or block.
  • one block may consist of four individual monomers, each defined by their own individual set of parentheses and number of repeat units present. All four sets of parentheses will be enclosed by a set of brackets, denoting that all four of these monomers combine in random, or near random, order to comprise the mixed block.
  • the randomly mixed block of [BCADDCBADABCDABC] would be represented in shorthand by [(A) 4 (B) 4 (C)4(D) 4 ].
  • Representative feed ratios include from about 1% to about 50%, from about 5% to about 50%, from about 10% to about 50%, from about 10% to about 40%, from about 15% to about 25%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35% or about 40%.
  • unit dosage form or “unit dose form” refers to a physically discrete unit of a formulation appropriate for the subject to be treated. It will be understood, however, that the total daily usage of the compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgement.
  • the specific effective dose level for any particular subject or organism will depend on a variety of factors including the disorder being treated and the severity of the disorder; activity of specific active agent employed; specific composition employed; age, body weight, general health, sex and diet of the subject; time of administration, and rate of excretion of the specific active agent employed; duration of treatment, drugs/ and or additional therapies used in combination or coincidental with specific compound(s) employed and like factors well known in the medical arts.
  • a “drug product” means a therapeutic agent, and one or more excipients selected from, but not limited to, tonicity agents, cryoprotectants, multiblock copolymers, stabilizing agents, antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, and vehicles.
  • excipients selected from, but not limited to, tonicity agents, cryoprotectants, multiblock copolymers, stabilizing agents, antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, and vehicles.
  • excipients selected from, but not limited to, tonicity agents, cryoprotectants, multiblock copolymers, stabilizing agents, antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives
  • a “cryoprotectant” or “cryoprotective agent” refers to compounds which either prevent freezing or prevent damage, or alteration to other compounds related to freezing. This includes, but is not limited to: sugars, monosaccharides, disaccharides, polyalcohols, amino acids, glycine, polyvinyl pyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffmose, sucralose, lactose, trehalose, dextran, and dextrose.
  • a "therapeutically effective amount” means an amount of a substance (e.g. a therapeutic agent, composition, and/or formulation) that elicits a desired biological response.
  • a therapeutically effective amount of a substance is an amount that is sufficient, when administered as part of a dosing regimen to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, slow the progression of and/or delay the onset of the disease, disorder, and/or condition.
  • the effective amount of a substance may vary depending on such factors as the desired biological endpoint, the substance to be delivered, the target cell or tissue, etc.
  • the effective amount of compound in a formulation to treat a disease, disorder, and/or condition is the amount that alleviates, ameliorates, relieves, inhibits, slows the progression of, delays onset of, reduces severity of and/or reduces incidence of one or more symptoms or features of the disease, disorder, and/or condition.
  • a "therapeutically effective amount" is at least a minimal amount of a compound, or composition containing a compound, which is sufficient for treating one or more symptoms of a disease or disorder associated with proliferative diseases, such as cancer.
  • patient refers to a mammal and includes human and animal subjects, such as domestic animals (e.g. horses, dogs, cats, etc.).
  • domestic animals e.g. horses, dogs, cats, etc.
  • treat refers to partially or completely alleviating, inhibiting, ameliorating, slowing the progression of and/or relieving a disease or disorder, or one or more symptoms of the disease or disorder.
  • treatment refers to partially or completely alleviating, inhibiting, ameliorating, slowing the progression of and/or relieving a disease or disorder, or one or more symptoms of the disease or disorder, as described herein.
  • treatment may be administered after one or more symptoms have developed.
  • treating includes slowing or halting the progression of a disease or disorder.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g. in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • treating includes preventing relapse or recurrence of a disease or disorder
  • Metalstatic used herein to describe cancer, refers to cancer that has spread from the part of the body where it started to other parts of the body.
  • “Locally advanced,” used herein to describe cancer, refers to cancer that has grown outside the organ it started in but has not yet spread to distant parts of the body.
  • a subject is said to have “failed” a therapy, or the term “failure” in the context of a previous treatment, as used herein means the subject relapses from the therapy, or is resistant or refractory to the therapy (e.g., progresses following or while on the therapy).
  • a subject having breast cancer that has not metastasized or advanced locally may not prevent the breast cancer from metastasizing or advancing locally. If the treatment does not prevent the breast cancer from metastasizing or advancing locally, and the breast cancer metastasizes and/or advances locally, the subject is said to have failed the treatment because the subject’s cancer progressed following or while on the treatment.
  • a subject previously diagnosed with metastatic or locally advanced breast cancer may be treated with a therapy for such cancer, but fail to respond to the therapy.
  • This subject too, is said to have failed the therapy because the subject is resistant or refractory to the therapy.
  • a subject that experiences remission following a therapy, but subsequently relapses is considered to have failed the prior therapy.
  • Prior therapy refers to any therapy given before the referenced therapy for a disease or condition, then a prior therapy includes drug(s), the referenced or subsequent therapy comprises one or more drugs that are different from the drug(s) of the prior therapy.
  • the subsequent therapy is a second-line therapy (i.e., the second therapy given for a disease or condition).
  • the subsequent therapy is a third-line therapy (i.e., the third therapy given for a disease or condition).
  • the subsequent therapy is a fourth-line therapy (i.e., the fourth therapy given for a disease or condition).
  • compositions are administered intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this disclosure may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3- butanediol.
  • a non-toxic parenterally acceptable diluent or solvent for example as a solution in 1,3- butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • the present disclosure provides a drug product comprising a formulation or composition described herein.
  • the present disclosure provides a composition comprising paclitaxel, and a copolymer of Formula I.
  • the present disclosure is directed to a composition comprising paclitaxel, and a copolymer of Formula I-a.
  • the present disclosure provides a composition comprising paclitaxel, and a copolymer of Formula I-b.
  • the composition further comprises a cryoprotectant.
  • the cryoprotectant is trehalose.
  • the weight loading of paclitaxel in drug product can have effects on reconstitution properties, stability, and manufacturing.
  • the present disclosure provides drug products with paclitaxel weight loadings from about 0.1% to about 30%.
  • One embodiment of the present disclosure provides a composition comprising paclitaxel, a copolymer of Formula I, and a cryoprotectant, wherein: the paclitaxel is about 1% by weight to about 50% by weight of the composition, a copolymer of Formula I is about 10% by weight to about 90% by weight of the composition, and the cryoprotectant is about 10% by weight to about 90% by weight of the composition.
  • One embodiment of the present disclosure provides a composition comprising paclitaxel, a copolymer of Formula I, and a cryoprotectant, wherein: the paclitaxel is about 10% by weight to about 20% by weight of the composition, a copolymer of Formula I is about 30% by weight to about 60% by weight of the composition, and the cryoprotectant is about 30% by weight to about 60% by weight of the composition.
  • One embodiment of the present disclosure provides a composition comprising paclitaxel, a copolymer of Formula I-a, and a cryoprotectant, wherein: the paclitaxel is about 1% by weight to about 50% by weight of the composition, a copolymer of Formula I-a is about 10% by weight to about 90% by weight of the composition, and the cryoprotectant is about 10% by weight to about 90% by weight of the composition.
  • One embodiment of the present disclosure provides a composition comprising paclitaxel, a copolymer of Formula I-a, and a cryoprotectant, wherein: the paclitaxel is about 10% by weight to about 20% by weight of the composition, a copolymer of Formula I-a is about 30% by weight to about 60% by weight of the composition, and the cryoprotectant is about 30% by weight to about 60% by weight of the composition.
  • One embodiment of the present disclosure provides a composition comprising paclitaxel, a copolymer of Formula I-b, and a cryoprotectant, wherein: the paclitaxel is about 1% by weight to about 50% by weight of the composition, a copolymer of Formula I-b is about 10% by weight to about 90% by weight of the composition, and the cryoprotectant is about 10% by weight to about 90% by weight of the composition.
  • One embodiment of the present disclosure provides a composition comprising paclitaxel, a copolymer of Formula I-b, and a cryoprotectant, wherein: the paclitaxel is about 10% by weight to about 20% by weight of the composition, a copolymer of Formula I-b is about 30% by weight to about 60% by weight of the composition, and the cryoprotectant is about 30% by weight to about 60% by weight of the composition.
  • One embodiment of the present disclosure provides a composition comprising paclitaxel, a copolymer of Formula I-b, and trehalose, wherein: the paclitaxel is about 1% by weight to about 50% by weight of the composition, a copolymer of Formula I-b is about 10% by weight to about 90% by weight of the composition, and the trehalose is about 10% by weight to about 90% by weight of the composition.
  • compositions of the disclosure further comprise a second therapeutic agent.
  • second therapeutic agents contemplated by this disclosure are useful in the treatment of cancer, and include, but are not limited to platinum-based chemotherapeutic agents, nucleoside analogues and microtubule-stabilizing agents.
  • the platinum-based chemotherapeutic agent is selected from carboplatin, cisplatin, oxaliplatin or nedaplatin.
  • the nucleoside analogue is selected from gemcitabine, fludarabine, cladribine clofarabine, cytarabine, fluorouracil, or capecitabine.
  • the microtubule-stabilizing agent is docetaxel or cabazitaxel.
  • compositions are formulated with a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers that may be used in the compositions of the disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene glycol and wool fat.
  • the compositions of the disclosure may be formulated for administration in any convenient way for use in human medicine.
  • compositions of the disclosure may be formulated for a variety of administration methods.
  • Administration methods contemplated by the disclosure include topical, systemic, or local administration.
  • therapeutic compositions of the disclosure may be formulated for parenteral administration (e.g., subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrastemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques), administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, or nasal administration.
  • parenteral administration e.g., subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrastemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques
  • administration by inhalation or insufflation either through the mouth or the nose
  • oral buccal, sublingual, transdermal, or nasal administration.
  • the compositions described herein may
  • the compositions are formulated for oral administration, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and the like.
  • inert base such as gelatin and glycerin, or sucrose and acacia
  • compositions of the disclosure may be mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • the drug products of this disclosure are formulated as liquid dosage forms for oral administration.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixers.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as water or other solvents, solubilizing agents and emulsifiers, such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyline glycol, oils (e.g., cottonseed, groundnut, com, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters or sorbitan and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents,
  • compositions of the disclosure are formulated for parenteral administration.
  • the compositions of the disclosure can be formulated for parenteral administration by further including one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use.
  • the compositions for parenteral administration may contain antioxidants, buffers, bacteriostats, and/or solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and non- aqueous vehicles which may be employed in the pharmaceutical compositions of the disclosure include water, Ringer’s solution, an isotonic salt solution, ethanol, polyols (such as 1,3- butanediol, glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • the compositions of the disclosure are intended for parenteral administration, and further comprise a vehicle selected from water, 1,3-butanediol, Ringer’s solution or an isotonic sodium chloride solution.
  • the compositions of the disclosure may be administered for slow, controlled or extended release.
  • extended release is widely recognized in the art of pharmaceutical sciences and is used herein to refer to a controlled release of an active compound or agent from a dosage form to an environment over (throughout or during) an extended period of time, e.g. greater than or equal to one hour.
  • An extended release dosage form will release drug at substantially constant rate over an extended period of time or a substantially constant amount of drug will be released incrementally over an extended period of time.
  • extended release used herein includes the terms “controlled release,” “prolonged release,” “sustained release,” “delayed release,” or “slow release” as these terms are used in the pharmaceutical sciences.
  • the extended release dosage is administered in the form of a patch or a pump.
  • the disclosure is directed to a unit dosage form comprising a formulation or composition described herein.
  • the present disclosure relates to pharmaceutical packs and/or kits comprising compositions described herein, or a unit dosage form comprising a provided composition, and a container (e.g. foil, or plastic package, or other suitable container).
  • a container e.g. foil, or plastic package, or other suitable container.
  • instructions for use may also be additionally provided in such kits.
  • compositions of the disclosure can be provided as a unit dosage form.
  • a vial comprising paclitaxel, and a copolymer of Formula l is a unit dosage form.
  • a vial comprising paclitaxel, and a copolymer of Formula I-a is a unit dosage form.
  • a vial comprising paclitaxel, and a copolymer of Formula I-b is a unit dosage form.
  • the vial further comprises a cryoprotectant.
  • the cryoprotectant is trehalose.
  • the disclosure is directed to a composition comprising paclitaxel, a copolymer of Formula I, and a cryoprotectant, wherein: the paclitaxel is present in about 20 mg to about 500 mg, a copolymer of Formula I is present in about 67 mg to about 1675 mg, and the cryoprotectant is present in about 67 mg to about 1675 mg.
  • the disclosure is directed to a composition comprising paclitaxel, a copolymer of Formula I, and a cryoprotectant, wherein: the paclitaxel is present in about 50 mg to about 200 mg, a copolymer of Formula I is present in about 118 mg to about 670 mg, and the cryoprotectant is about 118 mg to about 670 mg of the composition.
  • compositions of the disclosure comprise paclitaxel, a copolymer of Formula I-a, and a cryoprotectant, wherein: the paclitaxel is present in about 20 mg to about 500 mg, a copolymer of Formula I-a is present in about 67 mg to about 1675 mg, and the cryoprotectant is present in about 67 mg to about 1675 mg.
  • compositions of the disclosure comprise paclitaxel, a copolymer of Formula I-a, and a cryoprotectant, wherein: the paclitaxel is present in about 50 mg to about 200 mg, a copolymer of Formula I-a is present in about 118 mg to about 670 mg, and the cryoprotectant is present in about 118 mg to about 670 mg.
  • compositions of the disclosure comprise paclitaxel, a copolymer of Formula I-b, and a cryoprotectant, wherein: the paclitaxel is present in about 20 mg to about 500 mg, a copolymer of Formula I-b is present in about 67 mg to about 1675 mg , and the cryoprotectant is present in about 67 mg to about 1675 mg .
  • compositions of the disclosure comprise paclitaxel, a copolymer of Formula I-b, and a cryoprotectant, wherein: the paclitaxel is present in about 50 mg to about 200 mg, a copolymer of Formula I-b is present in about 118 mg to about 670 mg, and the cryoprotectant is present in about 118 mg to about 670 mg.
  • compositions of the disclosure comprise paclitaxel, a copolymer of Formula I-b, and trehalose, wherein: the paclitaxel is present in about 20 mg to about 500 mg, a copolymer of Formula I-b is present in about 67 mg to about 1675 mg, and the cryoprotectant is present in about 67 mg to about 1675 mg.
  • compositions of the disclosure comprise paclitaxel, a copolymer of Formula I-b, and a cryoprotectant, wherein: the paclitaxel is present in about 50 mg to about 200 mg, a copolymer of Formula I-b is present in about 118 mg to about 670 mg, and the cryoprotectant is present in about 118 mg to about 670 mg.
  • compositions of the disclosure can be provided as a unit dosage form.
  • a vial comprising paclitaxel, a copolymer of Formula I-b, and trehalose is a unit dosage form that may be provided.
  • the unit dosage form is selected from those in Table 1:
  • the unit dosage form is depicted in Table 2:
  • the unit dosage forms of the disclosure are provided in a sealed container. In some embodiments, the unit dosage forms of the disclosure are provided as lyophilized powders. In some embodiments, the unit dosage forms of the disclosure are provided as an infusion solution. In some embodiments, the infusion solution comprises a vehicle selected from water, 1,3-butanediol, Ringer's solution or an isotonic sodium chloride solution.
  • the unit dosage forms contemplated by the disclosure are provided as a kit.
  • the kit may comprise a first and a second container, wherein the first container comprises a composition as described herein, and the second container comprises a vehicle as described herein.
  • the first container comprises a composition as described herein as a lyophilized dry powder.
  • the kits of the disclosure may allow for the dissolution of the lyophilized compositions described herein immediately prior to the administration of those compositions to a subject in need thereof.
  • the disclosure is directed to methods for preparing drug products comprising paclitaxel and a copolymer of Formula I.
  • the disclosure is directed to a method for preparing a sterile, lyophilized drug product comprising paclitaxel and a copolymer of Formula I.
  • This drug product would be suitable for administration to a patient.
  • the disclosure is directed to a method for preparing a sterile, lyophilized drug product comprising paclitaxel, a copolymer of Formula I, and a cryoprotective agent.
  • the general method for providing said drug product comprises the steps of preparing a solution of a cryoprotectant and a copolymer of Formula I in a mixture of aqueous tert-butanol. Preparing a solution of paclitaxel in tert-butanol. Adding said paclitaxel solution to said solution of a cryoprotectant and a copolymer of Formula I, sterile filtering the resulting solution (e.g.
  • cryoprotective agents include, but are not limited to: sugars, monosaccharides, disaccharides, polyalcohols, amino acids, mannitol, glycine, polyvinyl pyrrolidine, polyethylene glycol, sorbitol, sucrose, glucose, raffmose, sucralose, lactose, trehalose, dextran, and dextrose.
  • cryoprotectant is trehalose.
  • the copolymer is Formula I-a. In another preferred embodiment the copolymer is Formula I-b.
  • the disclosure is directed to a method of preparing a unit dosage form comprising: a) dissolving paclitaxel, or a pharmaceutically acceptable salt thereof, a copolymer of Formula I and, optionally, a cryoprotectant, in aqueous tert-butanol, thereby forming a mixed solution; and b) optionally lyophilizing the mixed solution.
  • the disclosure is directed to a method of preparing a unit dosage form comprising: a) dissolving paclitaxel, or a pharmaceutically acceptable salt thereof, in tert-butanol, thereby forming a paclitaxel solution; b) dissolving a copolymer of Formula I and, optionally, a cryoprotectant, in an aqueous tert-butanol solution, thereby forming a copolymer solution; c) mixing the paclitaxel solution and the copolymer solution thereby forming a mixed solution; and d) optionally lyophilizing the mixed solution.
  • the disclosure is directed to a method of preparing a unit dosage form comprising: a) dissolving paclitaxel, or a pharmaceutically acceptable salt thereof, in tert-butanol, thereby forming a paclitaxel solution; b) dissolving a copolymer of Formula I and, optionally, a cryoprotectant, in an aqueous tert-butanol solution, thereby forming a copolymer solution; c) mixing the paclitaxel solution and the copolymer solution thereby forming a mixed solution; d) filtering the mixed solution, thereby forming a filtered solution; e) optionally lyophilizing the filtered solution.
  • compositions comprising paclitaxel are known to be useful for the treatment of patients with cancer, alone or in combination with other therapeutic agents and/or therapies. Such patients include those who have previously been treated for cancer, and those who have not previously been treated for cancer.
  • compositions of the disclosure comprise paclitaxel and a copolymer of Formula I and are useful in the treatment of a variety of cancers and other proliferative diseases.
  • compositions of the present disclosure are useful in the treatment a cancer including, but not limited to, the following: multiple myeloma, breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach (gastric), skin, squamous cellular carcinoma, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung, bone, colon, thyroid, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma (including uveal melanoma) sarcoma, bladder carcinoma, liver carcinoma (e.g., hepatocellular carcinoma (HCC)) and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin’s disease,
  • HCC
  • the cancer is ovarian cancer.
  • the cancer is breast cancer.
  • the cancer is non-small cell lung cancer.
  • the cancer is Kaposi sarcoma.
  • the cancer is metastatic breast cancer.
  • the cancer is advanced or metastatic non-small cell lung cancer.
  • the cancer is metastatic adenocarcinoma of the pancreas.
  • the cancer is a locally advanced cancer. In some embodiments the cancer is metastatic. In some embodiments the cancer is reoccurring. In some embodiments the cancer is relapsed. In some embodiments the cancer is refractory. [0085] In some embodiments the cancer is refractory to taxane treatment, anthracycline treatment, and/ or capecitabine treatment.
  • compositions of the disclosure are useful for the treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
  • prior therapy may have included an anthracycline unless clinically contraindicated.
  • compositions of the disclosure are useful for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
  • NSCLC locally advanced or metastatic non-small cell lung cancer
  • compositions of the disclosure are useful for the treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
  • compositions comprising a multiblock copolymer of Formula I and paclitaxel that may be administered to a patient in need thereof.
  • Routes of administration include, but are not limited to, parenterally, orally, sublingually, buccally, rectally, vaginally, by the ocular route, by the otic route, nasally, inhalation, nebulization, cutaneously, subcutaneously, topically, systemically, or transdermally.
  • the route of administration is intravenous.
  • the route of administration is via a central venous catheter.
  • the route of administration is via a peripheral venous catheter.
  • the present disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel wherein the treatment is metronomic.
  • the composition comprising a copolymer of Formula I and paclitaxel is administered over a period of at least one month, wherein the interval between each administration is no more than about a week and wherein the dose of paclitaxel at each administration is about 0.25% to about 25% of its maximum tolerated dose.
  • the present disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel wherein the treatment is given in a single, or on a repeating dosing schedule.
  • the composition comprising a copolymer of Formula I and paclitaxel is administered at least one of lx, 2x, 3x, 4x, 5x, 6x, or 7x a week.
  • the composition comprising a copolymer of Formula I and paclitaxel is administered at an interval of about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21, days 22 days. 23 days, 24 days, 25 days, 26 days, 27 days, 28 days.
  • the composition comprising a copolymer of Formula I and paclitaxel is administered over a period of about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, or 36 months.
  • the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel on day 1 of a 21 -day cycle. In a preferred embodiment, the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel on day 1 of a 28-day cycle. In another preferred embodiment, the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel on day 1, 8, and 15 of a 28-day cycle.
  • the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel on day 1, 8, and 15 of a 21 -day cycle. In another preferred embodiment, the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel once every 3 weeks.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel wherein the administration is performed over about 10 to about 90 minutes.
  • the administration is performed over about 1 to about 30 hours.
  • the administration is performed over about 30 to about 40 minutes.
  • the administration is performed over about 3 hours.
  • the administration is performed over about 24 hours.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel wherein the dose of paclitaxel is about 10 to about 300 mg/m 2 body surface area.
  • the dose of paclitaxel is about 50 mg/m 2 body surface area.
  • the dose of paclitaxel is about 75 mg/m 2 body surface area.
  • the dose of paclitaxel is about 90 mg/m 2 body surface area.
  • the dose of paclitaxel is about 100 mg/m 2 body surface area. In another preferred embodiment, the dose of paclitaxel is about 125 mg/m 2 body surface area. In another preferred embodiment, the dose of paclitaxel is about 130 mg/m 2 body surface area. In another preferred embodiment, the dose of paclitaxel is about 135 mg/m 2 body surface area. In another preferred embodiment, the dose of paclitaxel is about 175 mg/m 2 body surface area. In another preferred embodiment, the dose of paclitaxel is about 200 mg/m 2 body surface area. In another preferred embodiment, the dose of paclitaxel is 260 mg/m 2 body surface area.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with a platinum-based chemotherapeutic agent.
  • the composition comprising a copolymer of Formula I and paclitaxel with a platinum-based agent are administered simultaneously.
  • the composition comprising a copolymer of Formula I and paclitaxel with a platinum-based agent is administered sequentially.
  • the platinum-based agent is cisplatin.
  • the platinum-based agent is carboplatin.
  • carboplatin is administered at 3 AUC mg*min/mL.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with carboplatin wherein said composition is administered on days 1,8, and 15 of a 21 -day cycle and carboplatin is administered on day 1 of a 21 -day cycle immediately after administration of said composition.
  • a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with carboplatin wherein said composition is administered on days 1,8, and 15 of a 21 -day cycle and carboplatin is administered on day 1 of a 21 -day cycle immediately after administration of said composition.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with a nucleoside analog.
  • the composition comprising a copolymer of Formula I and paclitaxel and a nucleoside analog is administered simultaneously.
  • the composition comprising a copolymer of Formula I and paclitaxel and a nucleoside analog is administered sequentially.
  • the nucleoside analog is gemcitabine.
  • gemcitabine is administered at about 1000 to about 2000 mg/m 2 body surface area. In a preferred embodiment, gemcitabine is administered at about 1000 mg/m 2 body surface area. In another preferred embodiment, gemcitabine is administered at about 800 mg/m 2 body surface area. In a preferred embodiment, gemcitabine is administered at about 600 mg/m 2 body surface area.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with gemcitabine wherein said composition is administered on days 1,8, and 15 of a 28-day cycle and gemcitabine is administered on days 1, 8, and 15 of a 28-day cycle immediately after administration of said composition.
  • a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with gemcitabine wherein said composition is administered on days 1,8, and 15 of a 28-day cycle and gemcitabine is administered on days 1, 8, and 15 of a 28-day cycle immediately after administration of said composition.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with radiation therapy.
  • a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel in combination with radiation therapy.
  • the composition comprising a copolymer of Formula I and paclitaxel and radiation therapy are administered simultaneously.
  • the composition comprising a copolymer of Formula I and paclitaxel and radiation therapy are administered sequentially.
  • the disclosure is directed to a method for treating, stabilizing, or lessening the severity or progression of one or more proliferative diseases (e.g. cancer), wherein the method comprises administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel wherein the patient has a serum CA19-9 level (carbohydrate antigen 19-9) >59 ULN (upper limit of Normal).
  • a pharmaceutically acceptable composition comprising a copolymer of Formula I and paclitaxel wherein the patient has a serum CA19-9 level (carbohydrate antigen 19-9) >59 ULN (upper limit of Normal).
  • Paclitaxel HPLC Method - Assay and identity of paclitaxel was determined by high pressure liquid chromatography with UV detection at 227 nm.
  • the column utilized was a Phenomenex Gemini ® 5 ⁇ m C18 (110 A, 250 x 4.6 mm) at ambient temperature.
  • the mobile phase consisted of a 60:40 (v/v) mixture of 10 mM sodium phosphate and acetonitrile.
  • Paclitaxel drug product samples were prepared by dissolving the material in the mobile phase.
  • Paclitaxel standards were prepared by dissolving the material in acetonitrile. Separation was achieved with a flow rate of 1.0 mL/min for a total run time of 12 minutes.
  • Paclitaxel Weigh Loading Analysis was determined by comparing a standard curve of paclitaxel to a known concentration of drug product by HPLC analysis. Standards were prepared by dissolving paclitaxel in acetonitrile at concentrations of 10, 25, 50, 100, and 200 pg/mL. Paclitaxel drug product samples were prepared by dissolving the material in the mobile phase at a concentration of 1 mg/mL. The amount of paclitaxel in the drug product is then converted to weight percentage of the total based on the known quantity of drug product (i.e. 1 mg/mL).
  • the TYN-21 paclitaxel formulation (100 mg of 13 weight % paclitaxel) was reconstituted in saline (5.2 mL) to provide a solution with a paclitaxel concentration of 2.50 mg/mL.
  • Abraxane was reconstituted with 20 mL of saline according the package insert to provide a solution of 5 mg/mL paclitaxel which was diluted 1 : 1 (v/v) with saline to provide a solution with a paclitaxel concentration of 2.5 mg/mL.
  • Both the TYN-21 and Abraxane solutions were administered at 2.0 mL/kg by fast bolus IV infusion over 1-2 minutes via the tail vein to deliver a paclitaxel dose of 5.0 mg/kg.
  • Blood samples (-300 ⁇ L) were collected from jugular veins into BD Microtainer tubes containing K2EDTA at the end of infusion (EOI), and after 1 hour, 2 hours, 4 hours, and 8 hours. The blood samples were centrifuged at 4°C, 3000 g for 5 minutes within 30 minutes of collection. Plasma was collected into polypropylene tubes or 96-well plates, quickly frozen on dry ice and stored at -70 ⁇ 10 °C until LC -MS/MS analysis.
  • Quantification was determined by comparing a standard curve (6 non-zero concentrations) of paclitaxel in plasma against the samples from each time point.
  • Abraxane demonstrated a paclitaxel AUC of 4,648 ⁇ 1,306 ng*h/mL.
  • the C max of paclitaxel from Abraxane was 20,067 ⁇ 8,069 ng/mL.
  • the half-life of paclitaxel from Abraxane was 3.1 ⁇ 0.6 h.
  • the clearance of paclitaxel from Abraxane was 18.4 ⁇ 5.3 mL/min/kg.
  • TYN-21 demonstrated a paclitaxel AUC of 5,873 ⁇ 2,103 ng*h/mL.
  • the C max of paclitaxel from TYN- 21 was 18,367 ⁇ 7,410 ng/mL.
  • the half-life of paclitaxel from TYN-21 was 3.2 ⁇ 0.4 h.
  • the clearance of paclitaxel from TYN-21 was 15.3 ⁇ 4.6 mL/min/kg.
  • the pharmacokinetic data is shown in Figure 1.
  • TFS-2 poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )
  • trehalose a solution of 22.2 mg/mL of each component.
  • the pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH.
  • paclitaxel (603 mg) was dissolved in 30 mL of tert-butanol with the assistance of a sonicating water bath, to produce a solution of 20.1 mg/mL.
  • the two solutions were mixed and stirred for 15 minutes before filtering through a 0.22 ⁇ m PVDF filter.
  • the formulation solution was then transferred to 20 mL vials in 10 mL aliquots per vial, frozen at -80°C, and then lyophilized for 2 days. This yielded 4.2 g of a fragmented white cake containing paclitaxel at a weight loading of 12.9%.
  • Example 2 Paclitaxel Feed with TFS-2
  • 100 mg of TFS-2 (poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )) and 100 mg of trehalose were dissolved in 10 mL of 40:60 (v/v) tert-butanol : water to produce a solution of 10 mg/mL of each component.
  • the pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH.
  • paclitaxel (15 mg) was dissolved in 0.75 mL of tert-butanol with the assistance of a sonicating water bath, to produce a solution of 20 mg/mL.
  • the two solutions were mixed and stirred for 15 minutes before filtering through a 0.22 ⁇ m PVDF filter.
  • the formulation solution was frozen at -80°C, and then lyophilized for 2 days. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 7.51%.
  • Example 3 15% Paclitaxel Feed with TFS-1
  • the copolymer used was TFS-1 (poly(Sar) 175 -block-poly(d-Leu 35 -co-Tyr 25 )). This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 6.90%.
  • Example 4 20% Paclitaxel Feed with TFS-2
  • the drug solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 9.33%.
  • Example 5 20% Paclitaxel Feed with TFS-1
  • the copolymer used was TFS-1 (poly(Sar) 175 -block-poly(d-Leu 35 -co-Tyr 25 )); and the drug solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 9.20%.
  • Example 6 25% Paclitaxel Feed with TFS-2
  • 50 mg of TFS-2 (poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )) and 50 mg of trehalose were dissolved in 5 mL of 40:60 (v/v) tert-butanol: water to produce a solution of 10 mg/mL of each component.
  • the pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH.
  • paclitaxel (12.5 mg) was dissolved in 0.625 mL of tert-butanol with the assistance of a sonicating water bath, to produce a solution of 20 mg/mL.
  • the two solutions were mixed and stirred for 15 minutes before filtering through a 0.22 ⁇ m PVDF filter.
  • the formulation solution was frozen at -80°C, and then lyophilized for 2 days. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 11.4%.
  • Example 7 30% Paclitaxel Feed with TFS-2 [00111] Using the general method of Example 6 with the following exception: the drug solution consisted of 15 mg of paclitaxel dissolved in 0.75 mL of tert-butanol. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 14.6%.
  • Example 8 25% Paclitaxel Feed (at 4 mg/mL) with TFS-2
  • 100 mg of TFS-2 poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )
  • 100 mg of trehalose were dissolved in 5 mL of 35:65 (v/v) tert-butanol: water to produce a solution of 20 mg/mL of each component.
  • the pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH.
  • paclitaxel (25 mg) was dissolved in 1.25 mL of tert-butanol with the assistance of a sonicating water bath, to produce a solution of 20 mg/mL.
  • the two solutions were mixed and stirred for 15 minutes to produce a solution with a paclitaxel concentration of
  • Example 9 30% Paclitaxel Feed (at 4 mg/mL) with TFS-2
  • 100 mg of TFS-2 poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )
  • 100 mg of trehalose were dissolved in 6 mL of 35:65 (v/v) tert-butanol : water to produce a solution of 16.7 mg/mL of each component
  • the drug solution consisted of 30 mg of paclitaxel dissolved in 1.5 mL of tert- butanol. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 11.7%.
  • Example 8 Using the general method of Example 8 with the following exceptions: 100 mg of TFS-2 (poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )) and 100 mg of trehalose were dissolved in 7 mL of 35:65 (v/v)tert-butanol : water to produce a solution of 14.3 mg/mL of each component; and the drug solution consisted of 35 mg of paclitaxel dissolved in 1.75 mL of tert- butanol. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 14.3%.
  • TFS-2 poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )
  • trehalose 100 mg
  • 100 mg of trehalose were dissolved in 3.75 mL of 35:65 (v/v) tert-butanol : water to produce a solution of 26.7 mg/mL of each component.
  • the pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH.
  • paclitaxel 25 mg was dissolved in 1.25 mL of tert-butanol with the assistance of a sonicating water bath, to produce a solution of 20 mg/mL.
  • the two solutions were mixed and stirred for 15 minutes to produce a solution with a paclitaxel concentration of
  • Example 12 30% Paclitaxel Feed (at 5 mg/mL) with TFS-2
  • 100 mg of TFS-2 poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )
  • 100 mg of trehalose were dissolved in 4.5 mL of 35:65 (v/v) tert-butanol: water to produce a solution of 22.2 mg/mL of each component; and the drug solution consisted of 30 mg of paclitaxel dissolved in 1.5 mL of tert-butanol. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 11.5%.
  • Example 13 35% Paclitaxel Feed (at 5 mg/mL) with TFS-2
  • Example 11 Using the general method of Example 11 with the following exceptions: 100 mg of TFS-2 (poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )) and 100 mg of trehalose were dissolved in 5.25 mL of 35:65 (v/v) tert-butanol: water to produce a solution of 19.0 mg/mL of each component; and the drug solution consisted of 35 mg of paclitaxel dissolved in 1.75 mL of tert-butanol. This yielded the drug product as a fragmented white cake containing paclitaxel at a weight loading of 13.1%.
  • a jacketed round-bottom flask equipped to a circulating isopropanol/water bath was charged with N,N-dimethylformamide (100 mL).
  • the bath temperature was set to 20°C and stirred for ⁇ 15 mins to equilibrate before the addition of a solution of neopentylamine (3.31 mL of 300 mM in DMF, 86.6 mg, 1 equiv.) followed by the addition of sarcosine N- carboxyanhydride (20.0 g, 173.8 mmol, 175 equiv.).
  • the sides of the funnel and reaction vessel were rinsed down with additional DMF ( ⁇ 5 mL).
  • the reaction vessel was wrapped in aluminum foil to prevent light.
  • a jacketed round-bottom flask equipped to a circulating isopropanol/water bath was cooled to 20 °C prior to the addition of sarcosine N-carboxyanhydride (19.9 g, 172.9 mmol, 175 equiv.), followed by N,N-dimethylformamide (100 mL).
  • the mixture was stirred for ⁇ 30 seconds before the addition of neopentylamine (3.30 mL of 300 mM in DMF, 86.2 mg, 1 equiv.).
  • the reaction vessel was wrapped in aluminum foil to prevent exposure to light. After 15-20 mins, the reactions started to change from the initial clear and colorless solution to a light orange color that continues to intensify as the reaction proceeds.
  • IR was used to monitor the reaction progression via disappearance of the Sar NCA carbonyl stretches at -1850 and 1778 cm -1 , with the latter being the preferred wavenumber to monitor.
  • the reaction was -90% done after 6 hrs but was left to stir overnight. The next day, after a total of 19 hrs the reaction was complete.
  • the circulating bath temperature was increased to 25 °C prior to the addition of D-leucine N-carboxyanhydride (4.66 g, 29.66 mmol, 30 equiv.) and L-tyrosine N- carboxyanhydride (4.10 g, 19.78 mmol, 20 equiv.). Additional DMF (-5 mL) was used to rinse down the sides of the funnel and reaction vessel.
  • the solids were collected via filtration into a medium fritted glass funnel. The solids were transferred back to the original precipitation beaker along with additional EtOAc (250 mL) and slurried with vigorous stirring for 20 mins. The solids were collected in a new fritted glass funnel and then the same 20 mins slurrying procedure with was repeated with EtOAc (250 mL) once more. The product was dried on the frit in a vacuum oven at 90-100°C to yield 15.95 g (84.1%) of the title compound as a fine off-white dense powder.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le domaine des formulations de paclitaxel comprenant un copolymère poly(acide aminé) et leurs procédés de préparation et leurs méthodes d'utilisation. Les compositions selon l'invention sont des produits médicamenteux appropriés pour le traitement de cancers.
EP20704965.1A 2020-01-10 2020-01-10 Formulations de paclitaxel comprenant des polymères séquencés poly(acide aminé) Pending EP4087558A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/013187 WO2021141605A1 (fr) 2020-01-10 2020-01-10 Formulations de paclitaxel comprenant des polymères séquencés poly(acide aminé)

Publications (1)

Publication Number Publication Date
EP4087558A1 true EP4087558A1 (fr) 2022-11-16

Family

ID=69570818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20704965.1A Pending EP4087558A1 (fr) 2020-01-10 2020-01-10 Formulations de paclitaxel comprenant des polymères séquencés poly(acide aminé)

Country Status (2)

Country Link
EP (1) EP4087558A1 (fr)
WO (1) WO2021141605A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432641T3 (es) * 2007-04-30 2013-12-04 Intezyne Technologies Inc. Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos

Also Published As

Publication number Publication date
WO2021141605A1 (fr) 2021-07-15

Similar Documents

Publication Publication Date Title
AU2016202815B2 (en) Methods of treatment of pancreatic cancer
US10918619B1 (en) Formulations of paclitaxel with poly(amino acid) block polymers
CN104622794B (zh) 一种联合分子靶向药物和细胞毒药物的凝胶注射剂
EA007096B1 (ru) Применение cci-779 в качестве противоопухолевого средства
CN102458112A (zh) 纳米颗粒制剂及其用途
KR20070027510A (ko) Cci―779 및 리턱시맵의 항종양성 조합
TWI787201B (zh) 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組
RU2563997C2 (ru) Наночастицы оксалиплатина и способ их получения
US10080807B2 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin C
EP4087558A1 (fr) Formulations de paclitaxel comprenant des polymères séquencés poly(acide aminé)
CN114288290A (zh) 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
CN114040751A (zh) 针对微卫星稳定型结直肠癌通过协同性免疫原性细胞死亡促进抗肿瘤响应的槲皮素和土木香内酯的纳米共递送
US8124593B2 (en) Methods of treatment using sapacitabine
JP5843086B2 (ja) 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
US11857630B2 (en) Formulations of SN-38 with poly(amino acid) block polymers
KR102265488B1 (ko) 암 화학 요법시의 부작용 경감제
JP7468829B2 (ja) 癌を処置するための、癌治療剤と組み合わせたIRE1α阻害剤
CN115960834B (zh) 一种pd-1/ptx联合pd-1耐药模型建立的方法
TWI813931B (zh) 用於癌症治療之組合及其應用
US11291679B1 (en) Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
WO2022247846A1 (fr) Combinaison d'une composition d'albumine de docétaxel et d'un inhibiteur de point de contrôle immunitaire et son utilisation
WO2024145901A1 (fr) Micelle co-chargée de médicament, système de médicament synergique associé, son procédé de préparation, et son utilisation
CN116059167A (zh) 一种共载药胶束及其协同药物体系与制备方法和应用
WO2013171382A1 (fr) Médicament anti-cancéreux à libération prolongée à base de docetaxel

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)